← Back to Clinical Trials
Recruiting NCT06282601

NCT06282601 STUDY OF THE EFFECT OF RHYTHMIC AND NON-RHYTHMIC MUSICAL PRIMING ON THE SYNTAX CAPACITY OF PRESBYACOUSTIC OLDER ADULTS

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06282601
Status Recruiting
Phase
Sponsor Centre Hospitalier Universitaire Dijon
Condition Presbyacousie
Study Type INTERVENTIONAL
Enrollment 55 participants
Start Date 2025-08-02
Primary Completion 2027-10

Eligibility & Interventions

Sex All sexes
Min Age 70 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
AudiogramMusical priming for the syntax testTest MMSE

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 55 participants in total. It began in 2025-08-02 with a primary completion date of 2027-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Presbyacusis, or age-related hearing loss, is a public health problem, affecting 20% of men and 30% of women over the age of 70 according to the WHO. In the most incapacitating cases, hearing aids are required. Numerous studies have evaluated the benefits of hearing aids, particularly in terms of improved hearing and quality of life. However, the specific effect of music on language skills has not yet been studied in hearing-impaired older adults. In this context, it was decided to study the effect of musical priming on the syntactic abilities of adults aged 70 or older with presbyacusis. This study is based on the hypothesis that music priming with regular music optimizes the syntax language skills of people with presbyacusis, as has already been proven in adults and normal-hearing children.

Eligibility Criteria

Inclusion Criteria: * No objection to participation in the study * Men and women aged ≥ 70 years * Patients diagnosed with presbyacusis (age-related bilateral and symmetrical sensorineural hearing loss, all stages combined), with or without the use of a bilateral hearing aid. * If they use a hearing aid: hearing must have an average free-field fitted tonal threshold of 40 dB max and free-field fitted speech discrimination without lip-reading of 90-100% at 60dB in silence. * MMSE score ≥ 24/30 Exclusion Criteria: * Person under legal protection (curatorship, guardianship) * Person under court order * Adult unable to provide consent * Person with a neurocognitive disorder (post-stroke, dyslexia, dyspraxia) or neuro-psychiatric disorder (dementia, autism) * Severe sensorineural hearing loss with mean free-field threshold \> 40 dB and free-field speech discrimination without lip-reading of \< 90-100% at 60dB in silence * Asymmetrical sensorineural hearing loss due to an additional cause of hearing loss on one side. Secondary exclusion criteria: Person with syntax disorder (discovery of sentence comprehension or production disorders during syntax test)

Contact & Investigator

Central Contact

Alexis BOZORG-GRAYELI

✉ alexis.bozorggrayeli@chu-dijon.fr

📞 03 80 29 37 58

Frequently Asked Questions

Who can join the NCT06282601 clinical trial?

This trial is open to participants of all sexes, aged 70 Years or older, studying Presbyacousie. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06282601 currently recruiting?

Yes, NCT06282601 is actively recruiting participants. Contact the research team at alexis.bozorggrayeli@chu-dijon.fr for enrollment information.

Where is the NCT06282601 trial being conducted?

This trial is being conducted at Dijon, France.

Who is sponsoring the NCT06282601 clinical trial?

NCT06282601 is sponsored by Centre Hospitalier Universitaire Dijon. The trial plans to enroll 55 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology